Skip to main content
Journal cover image

Anti-angiogenic therapy in renal cell cancer.

Publication ,  Journal Article
Srinivasan, R; Armstrong, AJ; Dahut, W; George, DJ
Published in: BJU Int
May 2007

Angiogenesis is an important hallmark of RCC, reflected in the natural history, Histology, genetics and now therapeutics of this disease. Clearly, the pro-angiogenic growth factor VEGF is a functional drug target in RCC and many strategies to inhibit this biology have shown clinical benefit. Multi-targeted TKI that inhibit VEGFRs have been approved by the FDA as standard treatment for advanced RCC. Pharmacodynamyc studies suggest that these agents and others also have anti-angiogenic effects. Currently, studies combining VEGFR-targeted strategies with other anti-angiogenic agents, including anti-VEGF antibodies, IFN or mTOR inhibitors, are underway. However, to what extent the clinical benefit of anti-angiogenic strategies in RCC can be built upon is unknown.

Duke Scholars

Published In

BJU Int

DOI

ISSN

1464-4096

Publication Date

May 2007

Volume

99

Issue

5 Pt B

Start / End Page

1296 / 1300

Location

England

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Urology & Nephrology
  • Treatment Outcome
  • Neovascularization, Pathologic
  • Kidney Neoplasms
  • Humans
  • Dose-Response Relationship, Drug
  • Carcinoma, Renal Cell
  • Bevacizumab
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Srinivasan, R., Armstrong, A. J., Dahut, W., & George, D. J. (2007). Anti-angiogenic therapy in renal cell cancer. BJU Int, 99(5 Pt B), 1296–1300. https://doi.org/10.1111/j.1464-410X.2007.06834.x
Srinivasan, Ramaprasad, Andrew J. Armstrong, William Dahut, and Daniel J. George. “Anti-angiogenic therapy in renal cell cancer.BJU Int 99, no. 5 Pt B (May 2007): 1296–1300. https://doi.org/10.1111/j.1464-410X.2007.06834.x.
Srinivasan R, Armstrong AJ, Dahut W, George DJ. Anti-angiogenic therapy in renal cell cancer. BJU Int. 2007 May;99(5 Pt B):1296–300.
Srinivasan, Ramaprasad, et al. “Anti-angiogenic therapy in renal cell cancer.BJU Int, vol. 99, no. 5 Pt B, May 2007, pp. 1296–300. Pubmed, doi:10.1111/j.1464-410X.2007.06834.x.
Srinivasan R, Armstrong AJ, Dahut W, George DJ. Anti-angiogenic therapy in renal cell cancer. BJU Int. 2007 May;99(5 Pt B):1296–1300.
Journal cover image

Published In

BJU Int

DOI

ISSN

1464-4096

Publication Date

May 2007

Volume

99

Issue

5 Pt B

Start / End Page

1296 / 1300

Location

England

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Urology & Nephrology
  • Treatment Outcome
  • Neovascularization, Pathologic
  • Kidney Neoplasms
  • Humans
  • Dose-Response Relationship, Drug
  • Carcinoma, Renal Cell
  • Bevacizumab
  • Antineoplastic Agents